• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

In-vivo anti-reflux and raft properties of alginates.

作者信息

Lambert J R, Korman M G, Nicholson L, Chan J G

机构信息

Monash University Department of Medicine, Prince Henry's Hospital, Melbourne, Victoria, Australia.

出版信息

Aliment Pharmacol Ther. 1990 Dec;4(6):615-22. doi: 10.1111/j.1365-2036.1990.tb00509.x.

DOI:10.1111/j.1365-2036.1990.tb00509.x
PMID:2129648
Abstract

The comparative efficacy of two alginate-containing anti-reflux preparations (Gaviscon, Algicon) was assessed in a single blind crossover study of 20 patients with gastro-oesophageal reflux disease. The clinical efficacy study was preceded by two studies in healthy volunteers to assess the intragastric effects of Algicon and Gaviscon by pH measurement, endoscopic visualization and gamma scintigraphy. Algicon and Gaviscon were shown to form a raft in the fasting and fed human stomach, with Algicon alone having a potent antacid effect below and within the raft. Both Algicon and Gaviscon liquids significantly reduced the frequency and severity of reflux symptoms from baseline when given at their recommended doses (10 ml and 20 ml four times daily, respectively). There were no significant differences between Algicon and Gaviscon, although 12 patients preferred Algicon (vs 5 for Gaviscon) for control of reflux symptoms. It was concluded that both Algicon and Gaviscon were effective for the symptomatic control of gastro-oesophageal reflux disease.

摘要

相似文献

1
In-vivo anti-reflux and raft properties of alginates.
Aliment Pharmacol Ther. 1990 Dec;4(6):615-22. doi: 10.1111/j.1365-2036.1990.tb00509.x.
2
A comparison of gastro-oesophageal reflux in volunteers assessed by ambulatory pH and gamma monitoring after treatment with either Liquid Gaviscon or Algicon Suspension.在志愿者中,对使用液状盖胃平或氢氧化铝镁混悬液治疗后,通过动态pH监测和γ监测评估的胃食管反流情况进行比较。
Aliment Pharmacol Ther. 1992 Oct;6(5):579-88. doi: 10.1111/j.1365-2036.1992.tb00572.x.
3
Comparative study of Algicon versus Gaviscon in symptomatic gastro-oesophageal reflux.症状性胃食管反流中Algicon与Gaviscon的对比研究
Br J Clin Pract Suppl. 1989 Feb;66:52-5; discussion 61-4.
4
Algicon in the management of gastro-oesophageal reflux.阿尔吉康在胃食管反流管理中的应用
Br J Clin Pract Suppl. 1989 Feb;66:56-8; discussion 61-4.
5
Clinical and laboratory studies of the antacid and raft-forming properties of Rennie alginate suspension.雷尼藻酸盐混悬液抗酸及形成筏状结构特性的临床与实验室研究
Aliment Pharmacol Ther. 2006 Mar 15;23(6):759-65. doi: 10.1111/j.1365-2036.2006.02814.x.
6
Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients.餐后胃食管反流的抑制作用:基于磁共振成像和 pH 阻抗监测的藻酸盐(善卫喜 Advance)与简单抗酸剂的比较:健康志愿者的机制评估和反流患者的随机、对照、双盲研究
Aliment Pharmacol Ther. 2013 Jun;37(11):1093-102. doi: 10.1111/apt.12318. Epub 2013 Apr 18.
7
Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study.胃仙-U双重作用液(抗酸剂和藻酸盐)在控制胃食管反流病(GERD)患者餐后食管酸暴露方面比抗酸剂更有效:一项双盲交叉研究。
Aliment Pharmacol Ther. 2014 Sep;40(5):531-7. doi: 10.1111/apt.12857. Epub 2014 Jul 10.
8
Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.综述文章:藻酸盐筏剂在治疗烧心和胃酸反流中的应用
Aliment Pharmacol Ther. 2000 Jun;14(6):669-90. doi: 10.1046/j.1365-2036.2000.00759.x.
9
Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (Gaviscon Double Action).两项在健康受试者中进行的安慰剂对照交叉研究,评估藻酸盐-抗酸剂配方(善卫宁双效)对胃酸中和的作用。
Drug Dev Ind Pharm. 2019 Mar;45(3):430-438. doi: 10.1080/03639045.2018.1546314. Epub 2018 Dec 2.
10
Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.随机临床试验:酸口袋靶向藻酸盐抗酸剂(善卫司双效)缓解上胃肠道症状 - 胃食管反流病的双盲、安慰剂对照、初步研究。
Aliment Pharmacol Ther. 2014 Mar;39(6):595-602. doi: 10.1111/apt.12640. Epub 2014 Jan 28.

引用本文的文献

1
A Systematic Review on the Efficacy and Safety of Alginate-based Liquid Formulations in Reducing Gastroesophageal Reflux in Neonates and Infants.基于藻酸盐的液体制剂在降低新生儿和婴儿胃食管反流方面的疗效和安全性的系统评价
Acta Med Philipp. 2024 Feb 28;58(3):55-63. doi: 10.47895/amp.vi0.4618. eCollection 2024.
2
Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications.胃滞留技术与控释策略相结合:解决口服药物生物利用度和患者依从性问题的有效方案。
Pharmaceutics. 2021 Sep 30;13(10):1591. doi: 10.3390/pharmaceutics13101591.
3
The Effect of Alginate in Gastroesophageal Reflux in Infants.
藻酸盐在婴儿胃食管反流中的作用。
Paediatr Drugs. 2018 Dec;20(6):575-583. doi: 10.1007/s40272-018-0314-0.
4
Alginate controls heartburn in patients with erosive and nonerosive reflux disease.藻酸盐可控制糜烂性和非糜烂性反流病患者的胃灼热。
World J Gastroenterol. 2012 Aug 28;18(32):4371-8. doi: 10.3748/wjg.v18.i32.4371.
5
Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial.甘西康®与奥美拉唑治疗胃食管反流病症状的比较:一项直接比较的随机试验。
BMC Gastroenterol. 2012 Feb 23;12:18. doi: 10.1186/1471-230X-12-18.
6
A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms.海藻酸钠与无水氢氧化铝镁治疗胃食管反流症状患者的比较。
Dig Dis Sci. 2006 Nov;51(11):1904-9. doi: 10.1007/s10620-006-9284-0. Epub 2006 Sep 15.
7
Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.胃食管反流病治疗中的药代动力学优化
Clin Pharmacokinet. 1996 Nov;31(5):386-406. doi: 10.2165/00003088-199631050-00005.